Ozempic® (semaglutide) – New drug approval
December 5, 2017 – Novo Nordisk announced the FDA approval of Ozempic (semaglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
Download PDF
